Welcome to our dedicated page for EVOMMUNE news (Ticker: EVMN), a resource for investors and traders seeking the latest updates and insights on EVOMMUNE stock.
Evommune, Inc. develops clinical-stage biotechnology therapies targeting key drivers of chronic inflammatory diseases. News about EVMN centers on its pipeline, including EVO756, an oral small-molecule MRGPRX2 antagonist, and EVO301, a long-acting IL-18 binding protein fusion protein.
Company updates commonly cover clinical data, development plans and regulatory disclosures for chronic spontaneous urticaria, atopic dermatitis, ulcerative colitis and migraine prophylaxis. Recurring corporate news also includes quarterly financial results, capital-structure actions, business updates and public-company milestones following Evommune’s completed initial public offering.
Evommune (NYSE: EVMN) reported first-quarter 2026 results and program updates. Cash, cash equivalents and investments were $307.0M as of March 31, 2026. Enrollment is complete for Phase 2b EVO756 trials in CSU (N=160) and AD (N=120) with top-line readouts expected June 2026 and Q3 2026.
The company plans a mid-2026 Phase 2b in migraine and a mid-2027 Phase 2b subcutaneous trial for EVO301 following positive Phase 2a POC data. Q1 revenue was $0; net loss was $21.7M.
Evommune (NYSE: EVMN) will host a KOL webinar on April 13, 2026 at 11:00 a.m. PT (2:00 p.m. ET) to discuss the migraine treatment landscape and MRGPRX2 inhibition.
The company highlighted expansion of EVO756 into migraine prophylaxis and said a Phase 2b study is planned to begin in 3Q26. Presenters include Stewart Tepper, M.D., and Greg Dussor, Ph.D. A live Q&A will follow and the webcast will be archived for 90 days.
Evommune (NYSE: EVMN) reported positive Phase 2a proof-of-concept results for EVO301 in atopic dermatitis, showing a 33% placebo-adjusted EASI improvement and 23% placebo-adjusted IGA 0/1 at week 12 after two doses. The company also expects EVO756 Phase 2b top-line readouts in CSU in 2Q26 and AD in 2H26. Evommune closed a $125 million private placement and reported $216.7 million cash, extending runway through 2028; FY2025 revenue rose to $13.0 million from $7.0 million in 2024.
Evommune (NYSE: EVMN) entered a securities purchase agreement to sell 4,494,279 shares of common stock at $27.88 per share for gross proceeds of approximately $125 million. The private placement is expected to close on or about February 17, 2026, subject to customary conditions.
Placement agents and an advisor assisted the deal. Evommune intends to use net proceeds to advance its clinical development programs and for general corporate purposes, and agreed to file a registration statement for resale of the issued shares.
Evommune (NYSE: EVMN) reported positive top-line Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis. The 70-patient trial met its Bayesian primary endpoint with 99.8% posterior success and showed statistically significant, placebo-adjusted EASI reductions of 33% at week 12.
Additional highlights: 23% of patients achieved vIGA-AD 0/1 at week 12 versus 0% placebo, favorable PK supporting Q4-week dosing, no related serious adverse events, and plans for a Phase 2b subcutaneous dose-ranging trial.
Evommune (NYSE: EVMN) reported Q3 2025 results and a business update highlighting upcoming clinical milestones and its recent IPO. The company expects three Phase 2 readouts in 2026 across lead programs EVO756 (MRGPRX2 antagonist) and EVO301 (IL-18 inhibitor), including Phase 2b top-line data in CSU in 1H26 and Phase 2a/2b AD readouts in 1H–2H26. The company completed an IPO in November 2025, raising $172.5 million gross proceeds. Q3 financials: $10.0M revenue (collaboration with Maruho), $76.0M cash and investments as of Sept 30, 2025, R&D expense of $19.6M, and net loss of $12.5M.
Evommune (NYSE:EVMN) priced its initial public offering of 9,375,000 common shares at $16.00 per share, with gross proceeds expected to be $150 million before underwriting discounts, commissions, and expenses. Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares.
The shares are expected to begin trading on the New York Stock Exchange on November 6, 2025 under ticker EVMN, and the offering is expected to close on November 7, 2025, subject to customary closing conditions.
Evommune (NYSE:EVMN) announced the commencement of a proposed initial public offering on October 17, 2025 with a registration statement filed on Form S-1.
The company is offering 9,375,000 shares of common stock with an expected price range of $15.00 to $17.00 per share, and intends to grant underwriters a 30-day option for up to 1,406,250 additional shares. Evommune has applied to list its shares on the New York Stock Exchange under the symbol EVMN, and expects the registration statement to become automatically effective on November 5, 2025 pursuant to Section 8(a) of the Securities Act, subject to SEC and federal government operations.